Very young premenopausal women diagnosed with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained.
Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control.…
Glioblastoma, an area of urgent unmet clinical need, is the most common intrinsic brain cancer and frequently contains extrachromosomal DNA (ecDNA). EcDNA is increasingly recognized…
Sacituzumab govitecan (SG), a novel antibody-drug conjugate targeting Trop2, is approved for pre-treated metastatic triple negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial…
Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology…
Antibody drug conjugates (ADCs) represent one of the fastest growing therapeutic drug classes in solid tumor oncology. The ability to combine highly potent payload moieties…
The incidence of early-onset colorectal cancer (EOCRC; diagnosed <50 years of age) is rising globally; however, the causes underlying this trend are largely unknown. Colorectal…
We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We focused on mortality from…
Chylous effusion is a rare side effect observed during treatment with multikinase inhibitors (MKI) or selective RET tyrosine kinase inhibitors (TKIs) [1]. Pleura (12/22; 54%),…
18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool…
Immunotherapy has transformed the endometrial cancer treatment landscape , particularly for those exhibiting mismatch repair deficiency (MMRd/MSI-H). A growing body of evidence supports the integration…
